AR089931A1 - Composiciones farmaceuticas que contienen dimetilfumarato - Google Patents

Composiciones farmaceuticas que contienen dimetilfumarato

Info

Publication number
AR089931A1
AR089931A1 ARP130100385A ARP130100385A AR089931A1 AR 089931 A1 AR089931 A1 AR 089931A1 AR P130100385 A ARP130100385 A AR P130100385A AR P130100385 A ARP130100385 A AR P130100385A AR 089931 A1 AR089931 A1 AR 089931A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
compositions containing
containing dimethylfumarate
dimethylfumarate
dimethyl fumarate
Prior art date
Application number
ARP130100385A
Other languages
English (en)
Spanish (es)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of AR089931A1 publication Critical patent/AR089931A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP130100385A 2012-02-07 2013-02-07 Composiciones farmaceuticas que contienen dimetilfumarato AR089931A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596202P 2012-02-07 2012-02-07
US201261625621P 2012-04-17 2012-04-17
US201261723048P 2012-11-06 2012-11-06

Publications (1)

Publication Number Publication Date
AR089931A1 true AR089931A1 (es) 2014-10-01

Family

ID=48947963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100385A AR089931A1 (es) 2012-02-07 2013-02-07 Composiciones farmaceuticas que contienen dimetilfumarato

Country Status (24)

Country Link
US (7) US20130216615A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2811994A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP6189333B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102105217B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (5) CN114146081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR089931A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (6) AU2013203445C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014019462B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2862885C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014002077A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7141407A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA038152B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14014870A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1202261A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL233833B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX370785B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NI (1) NI201400086A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627980A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20150092A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014501750A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201404705YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (4) TWI697338B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013119677A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201405511B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
LT2139467T (lt) * 2007-02-08 2016-10-10 Biogen Ma Inc. Neuroapsauga, sergant demielinizuojančia liga
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
PT2718257T (pt) 2011-06-08 2018-02-26 Biogen Ma Inc Processo para a preparação de fumarato de dimetilo de alta pureza e cristalino
CA2862885C (en) * 2012-02-07 2020-06-02 Biogen Idec Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP6506174B2 (ja) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド 重水素置換されたフマル酸誘導体
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP4230264A3 (en) 2013-03-14 2024-03-06 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various deseases
WO2014143146A1 (en) * 2013-03-15 2014-09-18 Xenoport, Inc. Methods of administering monomethyl fumarate
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
CA3135273A1 (en) * 2013-12-12 2015-06-18 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
WO2015089420A1 (en) * 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3501510B1 (en) * 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016057133A1 (en) * 2014-10-08 2016-04-14 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
EA036075B1 (ru) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Схема дозирования для селективного агониста рецептора s1p1
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
HK1253050A1 (zh) * 2015-02-02 2019-06-06 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
WO2016124960A1 (en) * 2015-02-08 2016-08-11 Alkermes Pharma Ireland Limited Monomethylfumarate prodrug compositions
EP3270911A4 (en) * 2015-03-17 2018-08-29 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
AU2016273068A1 (en) 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
MA42196A (fr) * 2015-06-17 2018-04-25 Biogen Ma Inc Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
WO2017056107A1 (en) 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
MX2018005345A (es) * 2015-10-28 2018-08-14 Sun Pharmaceutical Ind Ltd Composiciones farmaceuticas de dimetil fumarato.
PL3397247T3 (pl) * 2015-12-31 2023-09-18 Zakłady Farmaceutyczne Polpharma Sa Sposób wytwarzania powlekanego dojelitowo granulatu zawierającego fumaran dimetylu
PL3407873T3 (pl) * 2016-01-28 2025-01-13 Zakłady Farmaceutyczne POLPHARMA S.A. Sposób otrzymywania granulatu zawierającego fumaran dimetylu
JP6902043B2 (ja) * 2016-02-11 2021-07-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチルを含む医薬ビーズ製剤
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
TR201616998A1 (en) 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
EP3595640A4 (en) * 2017-03-17 2020-09-23 Vitalis LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
JP7308763B2 (ja) 2017-06-23 2023-07-14 アルミラル・ソシエダッド・アノニマ フマル酸ジメチルを含む医薬組成物
WO2020055739A1 (en) * 2018-09-10 2020-03-19 Vitalis Llc Fumaric acid compositions with increased bioavailability and reduced side effects
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201818293A2 (tr) 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
WO2021142062A1 (en) * 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021183905A1 (en) 2020-03-13 2021-09-16 Simard Marc J Methods of treating multiple sclerosis
AU2021208602A1 (en) 2020-05-06 2022-12-15 Imcyse Sa Combination treatment for fumarate-related diseases
BR112023025435A2 (pt) * 2021-06-04 2024-02-27 Zim Laboratories Ltd Composições de liberação retardada de fumarato de dimetila
US20250282721A9 (en) 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
CN115590831A (zh) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） 一种富马酸二甲酯缓释微片及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
WO2003004001A1 (en) 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
CA2518734A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
EP1973530A2 (en) * 2005-12-30 2008-10-01 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
WO2008134013A2 (en) * 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical excipient complex
CN101917975B (zh) * 2007-12-21 2013-05-08 麦克内尔-Ppc股份有限公司 片剂的制造
US20100015220A1 (en) * 2008-05-20 2010-01-21 Wetterau John R Niacin and nsaid combination therapy
DK2334378T3 (da) * 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
EP2379062A1 (en) 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP2564839B1 (en) * 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US20120165404A1 (en) 2009-04-29 2012-06-28 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
DK2533634T3 (en) * 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
CA2862885C (en) * 2012-02-07 2020-06-02 Biogen Idec Ma Inc. Pharmaceutical compositions containing dimethyl fumarate

Also Published As

Publication number Publication date
CN104220061A (zh) 2014-12-17
BR112014019462A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
PE20150092A1 (es) 2015-02-06
EP2811994A4 (en) 2016-01-13
US20130216615A1 (en) 2013-08-22
TWI697338B (zh) 2020-07-01
AU2013203445B2 (en) 2016-10-20
CN114146079A (zh) 2022-03-08
NZ627980A (en) 2016-12-23
JP2017222705A (ja) 2017-12-21
CA2862885A1 (en) 2013-08-15
IL233833B (en) 2022-03-01
MX370785B (es) 2020-01-06
MX393165B (es) 2025-03-24
JP2022024048A (ja) 2022-02-08
AU2013204286A1 (en) 2013-08-22
CA2862885C (en) 2020-06-02
AU2018260937A1 (en) 2018-12-06
JP2015506377A (ja) 2015-03-02
TW202102205A (zh) 2021-01-16
ECSP14014870A (es) 2015-09-30
JP2019059732A (ja) 2019-04-18
AU2020244395A1 (en) 2020-10-29
TWI676475B (zh) 2019-11-11
US20180185319A1 (en) 2018-07-05
AU2013203445C1 (en) 2017-04-20
AU2013203445A1 (en) 2013-08-22
AU2018260937B2 (en) 2020-07-02
US20130295169A1 (en) 2013-11-07
SG11201404705YA (en) 2014-10-30
JP6430598B2 (ja) 2018-11-28
AU2017200394A1 (en) 2017-02-09
CO7141407A2 (es) 2014-12-12
EA038152B1 (ru) 2021-07-14
BR112014019462B1 (pt) 2022-03-22
BR112014019462A8 (pt) 2017-07-11
EA201491484A1 (ru) 2015-02-27
US20200222354A1 (en) 2020-07-16
US20190358190A1 (en) 2019-11-28
TW201818925A (zh) 2018-06-01
ZA201405511B (en) 2022-12-21
TW201345520A (zh) 2013-11-16
TW202231268A (zh) 2022-08-16
IL233833A0 (en) 2014-09-30
AU2013204286B2 (en) 2017-05-11
JP6189333B2 (ja) 2017-08-30
IL290378A (en) 2022-04-01
US20150209318A1 (en) 2015-07-30
CN113244185A (zh) 2021-08-13
AU2017208367A1 (en) 2017-08-17
WO2013119677A1 (en) 2013-08-15
AU2017200394B2 (en) 2018-12-06
AU2020244395B2 (en) 2022-11-24
EP2811994A1 (en) 2014-12-17
CN114146080A (zh) 2022-03-08
CL2014002077A1 (es) 2014-12-05
IL290378B2 (en) 2023-05-01
NI201400086A (es) 2015-01-08
PH12014501750A1 (en) 2014-11-10
MX2014009469A (es) 2014-09-22
US20180263946A1 (en) 2018-09-20
IL290378B1 (en) 2023-01-01
KR20150001726A (ko) 2015-01-06
KR102105217B1 (ko) 2020-06-01
HK1202261A1 (en) 2015-09-25
CN114146081A (zh) 2022-03-08

Similar Documents

Publication Publication Date Title
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
MX390779B (es) Composición farmacéutica.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
UY33937A (es) Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
UY34571A (es) Composiciones herbicidas que contienen bentazón y el inhibidor als y el inhibidor accasa.
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
CL2015002897A1 (es) Inhibidores de bace1
BR112014025041B8 (pt) Composição farmacêutica
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BR112014032759A2 (pt) composições lipídicas de racecadotril
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
FR2977256B1 (fr) Compositions de 2,4,4,4-tetrafluorobut-1-ene et de cis-1,1,1,4,4,4-hexafluorobut-2-ene
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CL2015000848A1 (es) Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12).
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
CR20150275A (es) Composición de difenidol de liberación prolongada
BR112015022940A2 (pt) composições líquidas de racecadotrila

Legal Events

Date Code Title Description
FC Refusal